Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 36,100 shares, a decline of 22.9% from the May 31st total of 46,800 shares. Based on an average daily volume of 51,900 shares, the short-interest ratio is currently 0.7 days.
Belite Bio Price Performance
BLTE stock traded down $0.82 during mid-day trading on Friday, reaching $45.68. 12,982 shares of the company traded hands, compared to its average volume of 79,004. Belite Bio has a 52-week low of $12.53 and a 52-week high of $50.15. The company has a market capitalization of $1.36 billion, a P/E ratio of -38.71 and a beta of -1.43. The company has a fifty day moving average price of $45.18 and a 200-day moving average price of $44.16.
Belite Bio (NASDAQ:BLTE – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.07. As a group, analysts forecast that Belite Bio will post -1.08 EPS for the current year.
Hedge Funds Weigh In On Belite Bio
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on BLTE shares. Benchmark reissued a “buy” rating and issued a $57.00 target price on shares of Belite Bio in a research report on Thursday, May 16th. HC Wainwright restated a “buy” rating and set a $59.00 price target on shares of Belite Bio in a report on Thursday, June 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Belite Bio in a research report on Thursday, June 20th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $44.83.
Get Our Latest Stock Analysis on Belite Bio
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Read More
- Five stocks we like better than Belite Bio
- The Role Economic Reports Play in a Successful Investment Strategy
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Why Are Stock Sectors Important to Successful Investing?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.